


MICRO-X

REIMAGINING MEDICAL IMAGING THROUGH PORTABLE CT

HealthInvest, Sydney
3 June 2026

Kingsley Hall
Chief Executive Officer



IMPORTANT NOTICE



SCOPE & LIMITATIONS

This Presentation has been prepared by Micro-X Limited (**Micro-X** or the **Company**) (ASX.MX1). The Presentation is a summary only and does not contain all the information about the Company's assets and liabilities, financial position and performance, profits and losses and prospects. This material in this Presentation may be supplemented with an oral presentation and/or other more detailed documents and should not be taken out of context. Although the information contained herein is based upon generally available information and has been obtained from third-party sources believed to be reliable, the Company does not guarantee its accuracy, and such information may be incomplete or condensed. The Company also refers to its filings made with the ASX Limited and the Australian Securities & Investments Commission.

FORWARD LOOKING INFORMATION

This Presentation contains forward looking and other subjective information. Such expectations, estimates, projections and information are not a guarantee of future performance and involve unknown risks and uncertainties. Actual results and developments will almost certainly differ from those expressed or implied and recipients of this Presentation should make their own assessment of the expectations, estimates, projections and the relevant assumptions and calculations upon which the opinions, estimates and projections are based. No representation or warranty, express or implied, is given as to the accuracy or completeness of the information or opinions contained in this Presentation and no liability whatsoever is accepted by the Company, or its directors, members, officers, employees, agents or advisers for any use or, or reliance placed upon, such information or opinions.

NOT AN OFFER FOR SECURITIES

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any shares nor does it constitute financial product or investment advice nor take into account your investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this Presentation but must make its own assessment of the Company and conduct its own investigations and analysis. Before making an investment in the Company, a prospective investor should consider whether such an investment is appropriate to their particular investment objectives and financial situation and seek appropriate advice, including legal, taxation and financial advice appropriate to their jurisdiction and circumstances.


UNITED STATES

The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the **Securities Act**), or under the securities laws of any state or other jurisdiction of the United States. Accordingly, the Company's securities may not be offered or sold, directly or indirectly, within the United States or to, or for the account of benefit of, U.S. Persons (as defined in Regulation S under the Securities Act as amended). This Presentation may not be distributed within the United States or to any person in the United States

OTHER JURISDICTIONS


This Presentation may only be accessed in other jurisdictions where it is legal to do so.

This presentation is approved by the Board of Micro-X



CREATING REVOLUTIONARY X-RAY IMAGING TO BETTER LIVES

Curious | Collaborative | Determined



NEXT-GENERATION CT IMAGING PLATFORM

MICRO-X

Technology enables entirely new medical CT imaging use cases

Proprietary Nano Electronic X-ray (NEX) platform

- A true structural technology advancement reducing size, weight and complexity
- Cold cathode carbon nanotube X-ray a technology leader
- Tube efficiency allows lower dose to patient

World-first portable CT architecture



- Bringing point-of-care imaging to settings previously not possible

Near term clinical and commercial catalysts

- Hospital human imaging trial to bring clinical validation of imaging quality
- Ambulance trial – point-of-care validation and pre-hospital clinical workflow
- Regulatory submissions

\$90M partner funding

- Strong partnerships connected to our target markets to de-risk R&D and drive commercial success



WHY PORTABLE CT MATTERS

MICRO-X

Size, weight and cost of conventional CT limits progress in global healthcare priorities

CT is a clinically accepted diagnostic tool for top global diseases

- Ischaemic heart disease- #1 cause of death
- Stroke – #2 cause of death
- Trachea, bronchus, lung cancers – Top 5 cause of death
- Trauma/Injury – Top cause of death under 45
- Respiratory disease – Major global disease burden
- Neurological disorders – Large ageing population burden

But CT is limited in where it can go


- Fixed hospital CT up to 2700kg, Mobile Stroke Unit CT up to 1000kg
- Considerable capex and opex, and are large, heavy, complex to operate

Rural & remote access is decreasing

- CT primarily in hospitals in highly populated areas
- In past 10 years, +100 US rural hospitals have closed, 600 at risk

Trends towards decentralisation of care




- Governments investing in mobile X-ray, stroke and lung cancer screening, advanced diagnostic vehicles – MX1 has a technology advantage



SOLVING THE CT TECHNOLOGY MOAT

Proprietary and customisable technology enables use across multiple applications

MICRO-X

NEX TUBES	HIGH VOLTAGE GENERATOR	MULTI-TUBE SWITCHING ARRAY	RECONSTRUCTION SOFTWARE
			
Cold cathode using proprietary carbon nanotube emitter 40% measured reduction in mAs Advantage in miniaturization without losing capability 100kV to 160kV used in current products	120kV and 160kV high voltage generators with solid state encapsulation to shrink the size and weight further enabling portability	CT architecture combines multiple NEX tubes with high-voltage switching electronics Design advantage – size, weight, speed and maintenance.	Proprietary reconstruction software developed with Johns Hopkins University using machine learning algorithms to create 3D CT imaging

ROVER – PROVEN TECHNOLOGY

Delivering on securing larger contracts and direct sales focus

Lighter, faster, reliable mobile X-ray

- Full medical performance in a mobile system
- 40% lower mAs¹

Large tender opportunities and GPOs


- \$3.3M order for Malaysian Ministry of Health - largest single order in Micro-X history
- Plan to build on sales momentum in South-East Asia markets
- Additional in country registrations and dealers to our network

Direct customer engagement


- Small and mid-sized hospitals where Rover is particularly well-suited with price point, portability, low mAs profile and minimal infrastructure requirements.
- Professional and college sports

2026 Rover update available mid-year

- Update to build on existing design and capability strengths and incorporates Voice of Customer
- Lower cost to produce leads to higher margin
- Lumen glass-free high-resolution detector, in bin charging, larger high-definition touchscreen interface



MICRO-X



1. Identical conditions with no compromise to image quality in independently conducted testing against GE AMX-IV and GE Navigate

HEAD CT – A NEW IMAGING CATEGORY

Hospital and ambulance trials ahead of FY2027 regulatory applications

MICRO-X

Taking diagnosis to the patient to save precious time


- ~70kg and able to fit in a standard road or air ambulance
- Designed to inform pre-hospital clinical diagnosis of type of stroke allowing for pre-hospital IV thrombolysis for ischemic stroke

Human imaging trial at two leading Australian stroke hospitals

- \$8M Australian Government Medical Research Future Fund non-dilutive grant, Australian Stroke Alliance partner
- First test bench installed at the Royal Melbourne Hospital, training and PACS integration completed
- Second test bench manufactured for install Royal Adelaide Hospital
- Pilot study to run over 6 to 9 months comparing stroke patient Head CT imaging with conventional CT scans

Ambulance trials

- \$4.4M Australian Government Industry Growth Program non-dilutive grant to support prototype development, integration and human trial in South Australian ambulance
- 6-month trial set to commence in 2026
- Additional air ambulance trial funding secured through Australian Stroke Alliance with Careflight and Royal Flying Doctors Service



FULL BODY CT – DESIGNING PROTOTYPE

Bringing full diagnostic CT scanning to the patient

MICRO-X

Up to \$25M development funding contract with US Govt biomedical research agency ARPA-H



- Initial funding of \$12.5M for first 2 years - up to \$25M for a total of 5 years
- Contract to design and deliver a lightweight and portable CT scanner for rural and remote use
- Competitive award won against multiple conventional CT vendors

Complete CT imaging solution - NEX Technology evolution

- Global issue of access to quality CT imaging – greater issue in rural and remote regions
- Lightweight and portable CT scanner - a “hospital on wheels”
- Builds on the core technology platform from the Head CT and Baggage CT projects

Staged work - all intellectual property retained

- Funded beyond vehicle integration and testing in rural US to FDA 510k submission



Above: Diagrammatic representation of proposed Full Body CT product and portable CT diagnostic solution for remote application

CORPORATE & FINANCIALS



\$22.2m

Contracted Payments FY26 onwards




\$13.1m

FY25 Total Revenue



\$5.4m

R&D Rebate FY25:
 \$5.1m received during FY25 & \$0.3m received during FY26



FINANCIALS & SHAREHOLDERS		SHARE CAPITAL (29 May 2026)	
Cash	\$3.5m (31 March 2026)	Share price	\$0.043 per share
Revenue	\$13.1m (FY2025) \$10.1m (HY2026)	Shares on issue – current Shares on issue – pro forma ⁽¹⁾	729.2 million 748.0 million
Institutions & Strategic Investors ⁽¹⁾	Acorn (9.5%), Perennial (8.9%), Billion Prima (8.6%), Varex (7.2%), Thorney (6.0%)	Performance rights Convertible notes	66.0 million 162.5k shares
Board & Mgmt ⁽¹⁾	2.5% excl. Performance rights	Market cap	\$32.1 million

WRAP UP

NEX Technology platform to scale

- 1 | Proprietary CT imaging platform
- 2 | Positioned at the intersection of CT and decentralised healthcare
- 3 | Multiple ways to win through funded developments
- 4 | Near term clinical and commercial catalysts
- 5 | NEX Technology enables portable CT

MICRO-X



MICRO-X

For more information visit: www.micro-x.com

Micro-X Limited

Kingsley Hall, Chief Executive Officer
Rebecca Puddy, Head of Corporate
Communications
Tel: +61 8 7099 3966
Email: media@micro-x.com

Investor Enquiries

Peter Dickman
Chief Financial Officer
Tel: +61 8 7099 3966
Email: pdickman@micro-x.com

